Provided by Tiger Trade Technology Pte. Ltd.

Atrium Therapeutics

13.14
+0.00500.04%
Volume:165.87K
Turnover:2.18M
Market Cap:203.79M
PE:-4.12
High:13.50
Open:13.21
Low:12.99
Close:13.13
52wk High:16.77
52wk Low:11.95
Shares:15.52M
Float Shares:11.14M
Volume Ratio:0.37
T/O Rate:1.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1910
EPS(LYR):-3.1905
ROE:-43.98%
ROA:-399.25%
PB:-3.25
PE(LYR):-4.12

Loading ...

N4 Pharma Rebrands as Thalia Therapeutics to Reflect RNA Therapeutics Focus

TIPRANKS
·
Mar 17

Ribo to present ex-hepatic delivery data at RNA Leaders Europe Conference

prnewswire
·
Mar 17

Novartis Issues Debt Offering to Help Fund $12B Acquisition of Avidity Biosciences

Dow Jones
·
Mar 17

Lucence, DxD Hub and NCCS launch $6 mil cancer diagnostics research collaboration

Nurdianah Md Nur
·
Mar 13

Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

GlobeNewswire
·
Mar 13

ProQR Posts 2025 Results as Axiomer RNA Editing Pipeline Advances and Cash Runway Extends to Mid-2027

TIPRANKS
·
Mar 12

Avidity Biosciences Initiated at Overweight by Wells Fargo

Dow Jones
·
Mar 11

U.S. RESEARCH ROUNDUP-Howmet Aerospace, Nike, Oracle

Reuters
·
Mar 11

Atrium Therapeutics initiated with an Overweight at Wells Fargo

TIPRANKS
·
Mar 11

Press Release: Korro Announces Oversubscribed $85 Million Private Placement

Dow Jones
·
Mar 09

PegBio’s Circular RNA GLP-1 Candidate Shows Month-Long Effect in First Human Trial

TIPRANKS
·
Mar 06

PYC Therapeutics Completes $47m Retail Entitlement Offer, Boosting Capital for RNA Programs

TIPRANKS
·
Mar 04

ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference

GlobeNewswire
·
Mar 04

Wave Life Sciences: Differentiated Obesity Franchise and RNA-Editing Pipeline Momentum Justify Buy Rating

TIPRANKS
·
Mar 02

Atrium Therapeutics Begins Operations With 2 Precision Cardiology Candidates

MT Newswires Live
·
Feb 27

Avidity Biosciences Completes Merger and Plans Nasdaq Delisting

TIPRANKS
·
Feb 27

Avidity Biosciences Spinoff Atrium Therapeutics Launches as Independent Public Company

Reuters
·
Feb 27

Novartis Completes Acquisition Of Avidity Biosciences

Reuters
·
Feb 27

Nasdaq to Suspend Avidity Biosciences Shares After Merger Delisting Request

Reuters
·
Feb 27

Novartis completes acquisition of Avidity Biosciences

TIPRANKS
·
Feb 27